Overview and Scope
Pheochromocytoma is a rare tumor that forms in the center of one or both adrenal glands. These tumors arise from the adrenal medulla cells, which are responsible for producing hormones such as adrenaline (epinephrine) and noradrenaline (norepinephrine). Pheochromocytomas can lead to excessive secretion of these hormones, causing symptoms like high blood pressure, rapid heartbeat, anxiety and related effects.
Sizing and Forecast
The pheochromocytoma market size has grown steadily in recent years. It will grow from $2.89 billion in 2023 to $3.03 billion in 2024 at a compound annual growth rate (CAGR) of 4.9%. The growth in the historic period can be attributed to rise in healthcare expenditure, increased diagnosis and awareness, genetic research, government initiatives.
The pheochromocytoma market size is expected to see steady growth in the next few years. It will grow to $3.56 billion in 2028 at a compound annual growth rate (CAGR) of 4.1%. The growth in the forecast period can be attributed to demand for combination therapies, investment in pheochromocytoma research and development, demand for minimally invasive pheochromocytoma treatments, high rare disease research initiatives. Major trends in the forecast period include increase in the number of drugs in clinical trials, advancements in diagnosis and treatment options, growing expertise in gene therapy, advancements in medical imaging.
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/pheochromocytoma-global-market-report
Segmentation & Regional Insights
The pheochromocytoma market covered in this report is segmented –
1) By Type: Adrenal Pheochromocytoma; Extra-Adrenal Pheochromocytoma
2) By Treatment: Medication; Surgery; Radionuclide Treatment; Other Treatments
3) By Diagnosis: Laboratory Tests; Imaging Tests; Genetic Testing
4) By End Users: Hospitals; Clinics; Research And Academic Institutes; Other End Users
North America was the largest region in the pheochromocytoma market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in pheochromocytoma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12909&type=smp
Major Driver Impacting Market Growth
The growing incidence rate of tumors is expected to propel the growth of the pheochromocytoma market going forward. Tumors are abnormal growths of cells that can be benign (non-cancerous) or malignant (cancerous). The rising cases of tumors and cancers emphasize the need for growing medical awareness, accurate diagnosis and tailored treatment strategies for managing desmoid pheochromocytoma effectively. For instance, in January 2023, according to the American Cancer Society, a US-based non-profit cancer advocacy organization, the number of cancer cases increased to 1,958,310 in 2023, reflecting a growth of 3.16% from 1,898,160 in 2021. Therefore, the growing incidence rate of tumors will drive the growth of the pheochromocytoma market going forward.
Key Industry Players
Major players in the pheochromocytoma market are Pfizer Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories, Takeda Pharmaceutical Company Limited, Merck KGaA, Baxter International Inc., Teva Pharmaceutical Company Limited, Mylan N.V., Bausch Health Companies Inc., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Apotex Inc., Sun Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, Endo International PLC, Exelixis Inc., Lupin Limited, Lantheus Holdings Inc., Curium Pharma, ANI Pharmaceuticals Inc., Jubilant Cadista Pharmaceuticals Inc., WellSpring Pharmaceutical Corporation, HRA Pharma SE.
The pheochromocytoma market report table of contents includes:
1. Executive Summary
2.Pheochromocytoma Market Characteristics
3.Pheochromocytoma Market Trends And Strategies
4.Pheochromocytoma Market analysis
5.Pheochromocytoma Market Size And Growth
6.Pheochromocytoma Segmentation
7. Pheochromocytoma Regional And Country Analysis
.
.
.
27.Pheochromocytoma Competitive Landscape And Company Profiles
28.Pheochromocytoma Key Mergers And Acquisitions
29.Pheochromocytoma Future Outlook and Potential Analysis
TOP MAJOR PLAYERS:
- Pfizer Inc.
- AbbVie Inc.
- Novartis AG
- Sanofi S.A.
- Bristol-Myers Squibb Company
- AstraZeneca PLC
Explore the trending research reports from TBRC:
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
The global market was valued at USD 2,814.75 Million in 2018.The global pheochromocytoma market is growing owing to the increasing investment by major companies to develop specific treatment options, high prevalence of pheochromocytoma, and an increasing number of clinical trials for drugs for pheochromocytoma.
Furthermore, the rapidly changing lifestyle, rising healthcare expenditure, and increasing incidence rate of rare tumors are also expected to fuel the market growth.
However, the stringent government regulations, lack of availability of specific drugs and lack of awareness regarding the disease are expected to restrain the growth of the global pheochromocytoma market.Request Sample Copy:https://www.marketresearchfuture.com/sample_request/8556Regional AnalysisThe market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The pheochromocytoma market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific.
The surgery segment is expected to hold the largest market share as it is the most preferred treatment option for pheochromocytoma.
According to the estimates, the highest contribution in the market size of NSCLC is from the United States followed by Japan, Germany, and the UK.One of the most exciting developments in lung cancer medicine is the introduction of targeted treatments.
The disease epidemiology included in the report provides historical as well as forecasted Non-Small Cell Lung Cancer epidemiology, which is segmented as Total Incident cases of NSCLC patients, Total Incident cases of NSCLC patients by Histology, Total Diagnosed cases of NSCLC patients by Stages, Total NSCLC cases of patients by Genetic mutation/Biomarkers, and Total Treated Cases of NSCLC patients by Line of Therapies scenario of NSCLC in the 7MM.
Click here to know more on Non-Small Cell Lung Cancer pipeline NSCLC report encloses the detailed analysis of Non-Small Cell Lung Cancer marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs.The therapies that are approved for the NSCLC treatment are Rozlytrek (Entrectinib), Imfinzi (Durvalumab), Opdivo (Nivolumab), Tecentriq (Atezolizumab), Keytruda (Pembrolizumab), Tafinlar (Dabrafenib) in combination with Mekinist (Trametinib), Tagrisso (osimertinib), Lorbrena/Lorviqua (Lorlatinib), Vizimpro (Dacomitinib), Alunbrig (Brigatinib), Alecensa (Alectinib), Vitrakvi (Larotrectinib), Portrazza (Necitumumab) along with many more.Drugs covered in the report are:-There are several key players robustly involved in developing potential products such asNazartinib (EGF816)Capmatinib (INC280)Tepmetko (tepotinib)MerestinibJNJ-61186372 (JNJ-6372)Vemurafenib Plus CobimetinibX-396 (Ensartinib)Tedopi (OSE2101)Selpercatinib (LY3527723/ LOXO-292)SAR408701Braftovi (encorafinib) + Mektovi (binimetinib)PADCEV (enfortumab vedotin/ASG-22ME)Pralsetinib (BLU-667)TAK-788: Canakinumab (ACZ885)Avelumab (Bavencio)Veliparib (ABT-888): Sitravatinib (MGCD516)TesevatinibRomiplostim: CabozantinibSym015AMG 510INCMGA00012 (MGA012)Libtayo (Cemiplimab)BavituximabM7824 (Bintrafusp alfa)And many othersKey Players covered in the report are:-Novartis PharmaceuticalsMerck KGaAEli Lilly and CompanyJanssen Research & DevelopmentHoffmann-La RocheXcoveryBeyondSpring PharmaceuticalsOSE ImmunotherapeuticsSanofiPfizerAstellas PharmaSeattle GeneticsBlueprint Medicines CorporationTakedaAbbVieKadmon CorporationAmgenSymphogenRegeneron PharmaceuticalsPeregrine PharmaceuticalsAvid BioservicesGlaxoSmithKlineAnd many othersThe report includes provides in depth analysis historical and forecasted Market Share (%) Distribution of NSCLC, Market Share (%) Distribution of NSCLC by Mutations/Biomarkers, Total Market Size of PD-L1 NSCLC, Total Market Size of BRAF NSCLC, Total Market Size of c-Met, Total Market Size of EGFR, Total Market Size of ALK as well.Market DriverMarket Barrier The reasons for buying this report:The report proffers an overview of pathophysiology, various diagnostic approaches and NSCLC treatment algorithm, including detailed chapters for marketed products and emerging therapies.Historical and forecasted Non-Small Cell Lung Cancer epidemiology in 7MM covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017-2030.Detailed historical and forecasted NSCLC market covering the United States, EU5 and Japan from 2017-2030.Pipeline analysis across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with comprehensive clinical profiles, key cross-competition, launch date along with product development activities.Detailed Non-Small Cell Lung Cancer market size by therapies, covering the United States, EU5 and Japan from 2017-2030.Reimbursement scenario and Key Opinion Leader Views Table of ContentsKey InsightsExecutive Summary of NSCLCSWOT Analysis of NSCLCNSCLC: Market Overview at a Glance4.1.
Total Market size of NSCLC in JapanALK-Mutation—Market Size21.1.
Report MethodologyDelveInsight CapabilitiesDisclaimerAbout DelveInsight Request a Webex Demo to get a walk-through of the report: https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-marketRelated Reports:Non-Small Cell Lung Cancer Epidemiology Forecast to 2030Non-Small Cell Lung Cancer Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020Non-Small Cell Lung Cancer Pipeline Insights, 2020About DelveInsightDelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the life science segment.
The Spirulina Market is expected to grow at a CAGR of 10.3% from 2020-2030, according to a new research report by Next Move Strategy ConsultingSpirulina is a blue green algae with high nutrient content, usually consumed by human & animals.
It is also used as a complementary diet ingredient in aquaculture & poultry feeds owing to the presence of high protein & vitamin content.According to the report, growth in health consciousness among people and the rising demand for dietary supplements are major factors driving the spirulina market growth.
Additionally, high penetration of spirulina in industries such as cosmetics and pharmaceutical owing to the advantageous properties such as anti-aging, anti-wrinkles and othersare bringing changes in market tends.However, low stability & poor sustainability of spirulina derived colours is expected to restrict the market growth.Moreover, growth in research & development activities followed by untapped market opportunities in developing economies are anticipated to provide numerous opportunities to the market players in the coming few years.On the basis of type, spirulina market share is segmented into Arthrospira Platensis and Arthrospira Maxima.
Arthrospira Maxima dominates the global Spirulina market and will be the dominant throughout the forecasted period.On the basis of application, the Spirulina market is categorised into Nutraceuticals, Food & Beverages, Cosmetics, Animal Feed, and Others.Food & Beverages segment is likely to develop significantly over the period of time owing to fast growing food & beverage industry.On the basis of drug formulation, the spirulina market is bifurcated into Powder, Tablet & Capsule, Liquid, and Granule & Gelling Agent.
Powder segment is expected to account for the major market share & dominate the market growth over the forecast period.North America dominates the spirulina market in terms of market size over the forecast period, owing to rising health consciousness among people.
Hansen Holding A/S, Algenol Biofuels Inc., Dongtai City Spirulina Bio-engineering Co., Ltd., Prolgae, Parry Neutraceuticals, Sensient Technologies Corporation, DDW Inc., Algatec and Naturex S.A.Browse key industry insights from the report, “Spirulina Market Size By Type (ArthrospiraPlatensis and Arthrospira Maxima) By Application (Nutraceuticals, Food & Beverages, Cosmetics, Animal Feed, and Others), By Drug Formulation (Powder, Tablet & Capsule, Liquid, and Granule & Gelling Agent)Regional Outlook (U.S., Canada, Germany, UK, France, Spain, Italy, Russia, China, India, Japan, Australia, Indonesia, Malaysia, South Korea, Brazil, Mexico, South Africa, Saudi Arabia, UAE, Kuwait), Growth Potential, Price Trends, Competitive Market Share & Forecast, 2020–2030” in detail along with the table of contents:Key Insights from the Spirulina Market Report:Asia Pacific is the fastest growing region in Spirulina market owing to the rising demand of spirulina from various industries such as cosmetics, food , healthcare and others and government initiatives to promote local spirulina production.The Food & Beverages segment dominates the market in terms of application and is expected to grow at a significant CAGR to maintain the lead till 2030.Some of the major players in the market are DIC Corporation, Cyanotech Corporation, Chr.
“Global Streetcar Market 2024” Report Provides Porters Five Forces Analysis Illustrates the Potency of Buyers & Suppliers Operating in the Industry & the Quantitative Analysis of The Global Market from 2019 to 2024 is Provided to Determine the Market Potential.
In this report, our team research the global Streetcar market by type, application,
Request a sample of Streetcar Market report @ http://www.arcognizance.com/enquiry-sample/445675
Geographically, global Streetcar market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer; the top players including
The U.S. SMS Marketing Market size is projected to value USD 12.6 billion until 2025.
It is expected to register a CAGR of 20.3% over the forecasted years, 2019 to 2025.
The increasing adoption of mobile phones coupled with the need for implementing marketing strategies through virtual mode is anticipated to drive the market growth in the upcoming years.
Key Players:Amobee,Marketo;EZ Texting;Chartboost;Infobip Ltd.;IBM Corporation Request free sample to get a complete analysis of top-performing companies @ https://www.millioninsights.com/industry-reports/us-sms-marketing-market/request-sample Market Synopsis of U.S. SMS Marketing Market: The end-use segment of retail dominated the global market with a share of more than 23.0% across the U.S. on account of increasing usage of SMS services by retailers for informing about various events and offers to their actual and potential customers.
On the other hand, the media & entertainment segment is anticipated to witness substantial growth with 22.0% CAGR from 2019 to 2025.
The enterprise segment of large enterprises dominated the global market in 2018 due to the shifting trend towards the implementation of these SMS marketing strategies for the engagement of customers.
Sulphur Bentonite - MARKET ADVISORY SERVICES
Sulphur Bentonite is an absorbent aluminium phyllosilicate clay consisting mostly of montmorillonite.
Sulphur Bentonite, is a yellow brown pastille.
But to achieve yields and more nutritious foods, crops need Sulphur (S).In recent few years, the manufacturers from India and Middle East are playing more and more important roles in global market, and in future, Middle & East and India will play more important roles in supplying Sulphur Bentonite to the whole world.
In this study, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Sulphur Bentonite.This report researches the worldwide Sulphur Bentonite market size (value, capacity, production and consumption) in key regions like United States, Europe, Asia Pacific (China, Japan) and other regions.This study categorizes the global Sulphur Bentonite breakdown data by manufacturers, region, type and application, also analyzes the market status, market share, growth rate, future trends, market drivers, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porter's Five Forces Analysis.
The following manufacturers Of Sulphur Bentonite are covered in this report:
